Navigation Links
CeNeRx BioPharma Completes $13 Million Series C Financing
Date:8/13/2010

RESEARCH TRIANGLE PARK, N.C., Aug. 13 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing.  Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing.  CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.

"These funds will support the Phase II trial of TriRima as monotherapy for treatment-resistant depression," said Barry Brand, Chief Executive Officer of CeNeRx.  "We are pleased with the continuing confidence and support of our investors and look forward to advancing the CeNeRx pipeline."

CeNeRx is preparing to conduct a Phase II trial with an improved formulation of its lead product candidate TriRima for treatment-resistant depression.  TriRima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A (MAO-A).  The triple action mechanism of TriRima elevates the levels of three key neurotransmitters that positively affect mood and anxiety, compared to the one or two neurotransmitters addressed by most current antidepressant drugs.  This triple action mechanism may benefit patients not responding to traditional single or dual action products, while the selectivity and reversibility of TriRima are expected to eliminate or reduce the risk of food-associated cardiovascular side effects of conventional MAO inhibitors.

About CeNeRx BioPharma

CeNeRx is a privately held clinical-stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system.  CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for treatment-resistant depression.  RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile.  The company's CNS pipeline also includes clinical-stage hypothalamic-pituitary adrenal (HPA) axis modulators for the treatment of a variety of CNS disorders including anxiety and depression; a small molecule, orally active agent for the prevention and treatment of neuropathies and neurodegenerative disorders; and a series of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity.  More information about CeNeRx can be found at www.cenerx.com.

Contact:

GendeLLindheim BioCom Partners

Barbara Lindheim

212 918 4650




'/>"/>
SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
2. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
3. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Almac Launch Biomarkers for Biopharma
6. Health Outcomes Data Essential to Biopharmaceutical Sales Process
7. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
8. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
9. Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences
10. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
11. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ ... Tissue Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - ... reach USD 779.8 Million by 2021 from USD 414.6 Million in ... of 2016 to 2021. Continue Reading ... ...
(Date:12/5/2016)... , December 5, 2016 According to a new ... and by Application - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", ... expected to reach $5,255 million by 2022, growing at a CAGR of 6.4% ... more than four-fifths share. Continue Reading ... ...
(Date:12/5/2016)... and PUNE, India , December 5, 2016 ... Allied Market Research, titled, "Global Cancer Biomarkers Market - Global ... cancer biomarkers market is projected to reach $15,737 million by ... 13.3% from 2016 to 2022. Omic technologies segment accounted for ... is expected to maintain its dominance during the forecast period. ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... ... lines. The goal of Castlewood Treatment Centers has always been to promote the ... as many people as possible. In that spirit, Castlewood has announced two new ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... Clinical Officer for the Florida Hospital West Florida Region. McGuinness brings experience in ... leading and engaging staff, physicians and leaders. , In her new role, that ...
(Date:12/5/2016)... ... ... has joined the Retina Group of New York (RGONY) specializing in uveitis and ... and has been providing tertiary medical and surgical retinal care on Long Island for over ... peers. Growing up in a family of doctors, Dr. Shah emulated the role of ...
(Date:12/5/2016)... ... December 05, 2016 , ... Z-Medica, LLC, a leading developer ... The American College of Surgeons (ACS) to provide basic bleeding control instructor training ... Basic” course is a pilot program that fulfills the intent of the White ...
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
Breaking Medicine News(10 mins):